What does development milestone payments mean?

Reflects contingent payments triggered by the achievement of specific clinical or regulatory milestones in the drug development process. These payments represent the ongoing cost of advancing a pipeline through phases such as clinical trials or FDA approval. Monitoring these helps investors gauge the progress and financial obligations associated with the company's R&D portfolio.

Citius Oncology, Inc. CTOR Development Milestone Payments

Development Milestone Payments at other companies

OS TherapiesOSTX

$22.38M0.0%

OS TherapiesOSTX

$22.38M0.0%

InsmedINSM

$15M—

Tarsus Pharmaceuticals, Inc.TARS

$67.5M0.0%

AMP

Amphastar PharmaceuticalsAMPH

$14M—

InsmedINSM

$15M—

Other financials

Income statement

See full

Revenue$1.7M—

Gross profit$1.3M—

Operating income-$28.6M-283%

Net income-$26.6M-244%

EPS (diluted)-$0.27-145%

Balance sheet

See full

Cash & equivalents$2.6M+2,350,466%

Total equity$35.3M-1.0%

Total assets$100.7M+10.1%

Cash flow

See full

Operating cash flow-$3.8M-179%

Valuation

See full

Market cap$60.45M-74.7%

Returns & leverage

See full

Return on equity-119.9%+46.7pp

Current ratio0.5×+0.1×

Where this comes from

Reported directly by Citius Oncology, Inc. in its filing.

Tagged under the XBRL concept ctor:DevelopmentMilestonePayments.

The official record: Citius Oncology, Inc.’s 10-Q, filed February 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Citius Oncology, Inc.'s development milestone payments.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Citius Oncology, Inc.'s development milestone payments?: Citius Oncology, Inc. (CTOR) reported development milestone payments of $70M in Q4 2025.
What does development milestone payments mean?: Reflects contingent payments triggered by the achievement of specific clinical or regulatory milestones in the drug development process. These payments represent the ongoing cost of advancing a pipeline through phases such as clinical trials or FDA approval. Monitoring these helps investors gauge the progress and financial obligations associated with the company's R&D portfolio.